View Latest Medical and Pharma Bids and Tenders

Supply of Medicine and Medical / Surgical equipments : Elisa Test kit for detection of HIV P24 antigen\nand antibodies to HIV; HIV 2 and HIV vi sub\ntype „O‟ antigen\n1. Test kit should detect of HIV P24 antigen\nand antibodies to HIV-1 (groups M and O)\nand HIV-2 inhuman serum or plasma.\n2. Number of tests shall be performed =480\ntests per kit\n3. Sensitivity should be 100%\n4. Specificity should be more than 99%\n5. Residual shelf life at the time of delivery\nshould be minimum of 18 months\n6. Each test kit should include adequate\npositive and negative controls\n7. Shall give a color change once serum is\nadded to the reagents.\n8. Precautions must be taken to maintain the\ncold chain while transportation until it reaches\nthe blood bank, as these\nreagents are kept at 2-6C.\n9. Reagent brochure, labels and any other\ninformation provided should be in English\nlanguage.\n10. Reagent shall contain FDA certification\nand/or WHO certification/ EU Quality\ncertification /free sales certificate and\ncertificate of use in the country in country of\norigin/ end user evaluation certificate/ or free\nsales certificate in USA, UK, France, Germany,\nCanada, New Zealand or Australia with\nstandard quality certificates etc .

Supply of Medicine and Medical / Surgical equipments : ELISA test kit for the detection of Antigen &\nAntibodies to HCV 4th Gen (Hepatitis C Virus)\n1. Test kit should detect HCV antigen and\nantibodies in human serum or plasma.\n2. Number of tests shall be performed =480\ntests per kit\n3. Sensitivity should be 100%\n4. Specificity should be more than 99%\n5. Residual shelf life at the time of delivery\nshould be minimum of 18 months\n6. Each test kit should include adequate\nnegative and positive controls\n7. Shall give a color change once serum is\nadded to the reagents.\n8. Precautions must be taken to maintain the\ncold chain while transportation until it reaches\nthe blood bank, as thesem reagents are kept\nat 2-6 C.\n9. Reagent brochure, labels and any other\ninformation provided should be in English\nlanguage.\n10. Reagent shall contain FDA certification\nand/or WHO certification/ EU Quality\ncertification /free sales certificate and\ncertificate of use in the country in country of\norigin/end user evaluation certificate/ or free\nsales certificate in USA, UK, France, Germany,\nCanada, New Zealand or Australia with\nstandard quality certificates etc .

Supply of Medicine and Medical / Surgical equipments : Anti C Sera 5ml/vial\n1. The method of manufacture should result\nin a product within an immediate container\nthat is homogeneous and free of properties\nwhich adversely affect its intended use\nthroughout its recommended shelf life. The\nreagent should have no precipitate, particles\nor fibrin gel.\n2. Each batch or sub-batch should be\nspecifically identified by a distinctive\ncombination of numbers and/or letters (batch\nreference) which permits its history to be\ntraced.\n3. Reagents should be produced by a\nvalidated process that is shown to be suitable\nfor the intended purpose.\n4. Volume should be mentioned in milliliters\n(ml) on immediate container\n5. Absence of rouleaux formation, prozone\nand haemolysis.\n6. Labelling requirements; A. Should have a\nlabel on the immediate container B. Printing\non all final container labels shall be in solid\nblack. C. The label fixed to the immediate\ncontainer of a reagent should leave\nuncovered sufficient area of the full length or\ncircumference of the container to allow ready\nvisual inspection of the contents. D. The\nspecificity of the reagent for blood group\nserology should be of a print size which is\nclearly legible. The print size of other\ninformation on the label should not exceed\nthat used for the specificity of the reagent. E.\nShould include Lot number and sub lot\ndesignations, if available F. Expiry date\nshould be mentioned. G. Should mention the\nrecommended storage temperature (2-6 C)\n7. Precautions must be taken to maintain the\ncold chain while transportation until it reaches\nthe blood bank, as these reagents are kept at\n2-6C.\n8. Reagent shall contain FDA and/or WHO\ncertification/ country of origin certificate and\ncertificate of use in the country of origin/end\nuser evaluation certificate/free sales\ncertificate in USA, UK, France, Germany,\nCanada, New Zealand or Australia with\nstandard quality certificates.\n9. Reagent brochure, l

Supply of Medicine and Medical / Surgical equipments : Anti-A Blood grouping Reagent- Monoclonal-\nDirect Agglutining 10ml\n1. The method of manufacture should result\nin a product within an immediate container\nthat is homogeneous and free of properties\nwhich adversely affect its intended use\nthroughout its recommended shelf life. The\nreagent should have no precipitate, particles\nor fibrin gel.\n2. Each batch or sub-batch should be\nspecifically identified by a distinctive\ncombination of numbers and/or letters (batch\nreference) which permits its history to be\ntraced.\n3. Reagents should be produced by a\nvalidated process that is shown to be suitable\nfor the intended purpose.\n4. Volume should be mentioned in milliliters\n(ml) on immediate container\n5. Absence of rouleaux formation, prozone\nand haemolysis.\n6. Labelling requirements; A. Should have a\nlabel on the immediate container B. Printing\non all final container labels shall be in solid\nblack. C. The label fixed to the immediate\ncontainer of a reagent should leave\nuncovered sufficient area of the full length or\ncircumference of the container to allow ready\nvisual inspection of the contents. D. The\nspecificity of the reagent for blood group\nserology should be of a print size which is\nclearly legible. The print size of other\ninformation on the label should not exceed\nthat used for the specificity of the reagent.\nE. Should include Lot number and sub lot\ndesignations, if available F. Expiry date\nshould be mentioned. G. Should mention the\nrecommended storage temperature (2-6 C)\n7. Precautions must be taken to maintain the\ncold chain while transportation until it reaches\nthe blood bank, as these reagents are kept at etc .

Supply of Medicine and Medical / Surgical equipments : ELISA kit for Hepatitis B, HBs antigen detection\nin human serum or plasma 480 tests/kit\n1. Test kit should detect surface antigen of the\nHepatitis B virus (HBs Ag)in human serum or\nplasma.\n2. Number of tests shall be performed =480\ntests per kit.\n3. Sensitivity should be 100%.\n4. Specificity should be more than 99%.\n5. Residual shelf life at the time of delivery\nshould be minimum of 18 months.\n6. Each test kit should include adequate\nnegative and positive controls.\n7. Shall give a color change once serum/plasma\nis added to the reagents.\n8. Precautions must be taken to maintain the\ncold chain while transportation until it reaches\nthe blood bank, as these reagents are kept at\n2-6 C.\n9. Reagent brochure, labels and any other\ninformation provided should be in English\nlanguage.\n10. Reagent shall contain FDA certification\nand/or WHO certification/ EU Quality\ncertification /free sales certificate and certificate\nof use in the country in country of origin/end\nuser evaluation certificate/ or free sales\ncertificate in USA, UK, France, Germany,\nCanada, New Zealand or Australia with\nstandard quality certificates.\nPacking : 1 pack etc .

Supply of Medicine and Medical / Surgical equipments : HIV Ag/Ab Combo Reagent for Analyzer\nCMIA technology-based HIV Ag/Ab Combo\nassay for blood donor screening.\nThe reagent kit shall be compatible with\nAlinitys Analyzer. CMIA HIV Ag/Ab Combo 4th\ngeneration assay should use two step\nchemiluminescent microparticle enzyme\nimmunoassay (CMIA) used for the\nsimultaneous qualitative detection of human\nimmunodeficiency virus (HIV) p24 antigen and\nantibodies to HIV type 1 (HIV-1 group M and\ngroup O and/or type 2 (HIV-2) in human serum\nand plasma, including specimens collected\npostmortem (non-heart-beating) to be used on\nAlinity s system for blood donor screening\npurposes. Ready To Use cartridges for the\neasy of use and less manual intervention.\nEach cartridge should be able to perform 500\ntests.\nThe reagent kit must be FDA approved for\nblood donor screening of HIV and certificates\nshall be attached.\nThe reagent kit must be NMRA approved for\nblood donor screening of HIV for blood and\nplasma donors.\nAll certificates of NMRA mentioning donor\nscreening purpose must be submitted for HIV\nAg/Ab Combo reagents.\nThe CMIA technology-based HIV Ag/Ab Combo\nassay should include calibrator kits, control\nkits, release control kits and reaction vessels\nalong with the reagent kits. At the time of\ndelivery expiery time shall be minimum of 10\nmonths.\nPacking : 500 tests etc .

Supply of Medicine and Medical / Surgical equipments : Phenotyping solid-phase immunoassay for\nanti-HLA Class I antibody screening {Analyte-\nspecific Reagent (ASR)}compatible with\nLuminex xMAP microbead technology-based\nFLEXMAP-3D compact flow cytometry\nplatform, together with comprehensive\naccessories (if applicable), software, technical\nassistance, capacity building & application\nsupport. [refer to special order conditions for\nprioritizing and/or selecting primary\n/predominant workflow; solution offering\nobjective & best quality evidence for clinical\n/technical impact and/or effect of assay\ngamut, sensitivity, specificity, comparative\nvariability, best demonstrating native\nreactivity, lowest interference, best quality\ncontrol parameters, particularly when\ncompared to superior /comparative\ntechnologies together with most intuitive\n/capable software & best technical support\nsolution to be selected as the predominant\n/primary solution]\nPacking : 100 Reactions etc .

Dhs/L/Ww/03/26 - Alternative Source Dna Extraction Reagents For Nbts

Dhs/L/Ww/02/26 - Machine Specific Reagents (One Lambda Labscan 100) For Nbts

Dhs/L/Ww/03/26 - Alternative Source Dna Extraction Reagents For Nbts